December 2015

Heart disease and stroke were the number one and number two killers worldwide in 2013, reveals a new report.

Training your kids to chew food slowly can be an inexpensive and easy way to help them stay in shape, suggests new research.

A Chinese man has donated hemopoietic stem cells (HSCs) to a patient with blood disease in Malaysia, a media report said on Thursday.

Parent-led intervention has been found promising in helping children suffering from autism in India and Pakistan initiate communication with their parents, a new study says.

The appetite-regulating hormone ghrelin could be used to treat an advanced form of peripheral artery disease characterised by pain at rest, non-healing ulcers, and gangrene, say researchers, including one of Indian-origin.

The Supreme Court on Wednesday said the testing of Maggi noodles samples as directed by the National Consumer Disputes Redressal Commission (NCDRC) will now be undertaken by the Mysuru-based Central Food Technological Research Institute lab.

An Indian-origin professor has created a 'supercondom' that can help combat the deadly virus that cause AIDS and also enhance sexual pleasure.

Natco Pharma Limited  announced that it has received approval for the generic version of ledipasvir+sofosbuvir combination from Drugs Controller General (India). NATCO plans to launch this combination drug immediately, under its brand name Hepcinat LP, and through its strategic partners in India.

Matinas BioPharma Holding Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibacterial development candidate, MAT2501, as a Qualified Infectious Disease Product (QIDP) for the treatment of non-tuberculous mycobacterium (NTM) infections.

Antares Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for 4 mg/0.5 mL and 6 mg/0.5 mL Sumatriptan Injection USP in adults for the acute treatment of migraine and cluster headache when a clear diagnosis has been established. The reference listed drug in the ANDA was GlaxoSmithKline’s Imitrex® Injection. Sumatriptan Injection USP represents the Company’s first ANDA approval of a complex generic and second product approved using the VIBEX® auto injector platform. In accordance with our previously disclosed agreement, Teva Pharmaceutical Industries, Ltd. (Teva) will distribute the product through their U.S. generic division and share the profits equally with Antares Pharma.